Publications by authors named "S J Nicholls"

Potentially zoonotic Mycobacterium spp. are impacting freshwater ornamental fish in Trinidad and Tobago. Clinical cases presented at the Aquatic Animal Health Unit of The University of the West Indies, School of Veterinary Medicine, from September 2011 to September 2018 indicated the presence of piscine mycobacteriosis in freshwater ornamental fish from locations throughout Trinidad and Tobago.

View Article and Find Full Text PDF

Purpose Of Review: Lowering low-density lipoprotein (LDL)-cholesterol reduces cardiovascular risk. International lipid management guidelines recommend LDL-cholesterol goals or thresholds for initiating lipid-lowering therapy. However, contemporary real-world studies have shown that many high- and very high-risk patients are not attaining LDL-cholesterol goals and are not receiving intensive lipid-lowering therapies.

View Article and Find Full Text PDF
Article Synopsis
  • Atherosclerotic cardiovascular disease (ASCVD) is a major global health issue, with high levels of low-density lipoprotein cholesterol (LDL-C) linked to increased cardiovascular risk.
  • Numerous studies confirm that lipid-lowering therapies (LLT) are effective; however, there is a gap between guidelines and actual clinical practice regarding LDL-C targets.
  • The review suggests new strategies beyond traditional LDL-C management, such as combination therapies and emerging drugs, while also introducing the potential use of polygenic risk scores for personalized treatment approaches in ASCVD prevention.
View Article and Find Full Text PDF

There is a new awareness of the widespread nature of metabolic dysfunction-associated steatotic liver disease (MASLD) and its connection to cardiovascular disease (CVD). This has catalyzed collaboration between cardiologists, hepatologists, endocrinologists, and the wider multidisciplinary team to address the need for earlier identification of those with MASLD who are at increased risk for CVD. The overlap in the pathophysiologic processes and parallel prevalence of CVD, metabolic syndrome, and MASLD highlight the multisystem consequences of poor cardiovascular-liver-metabolic health.

View Article and Find Full Text PDF
Article Synopsis
  • * Current tests for measuring Lp(a) often assess total apo(a), which may not accurately reflect Lp(a) levels or the effects of new treatments.
  • * A new immunoassay developed for measuring Lp(a) particles showed better accuracy, indicating that muvalaplin's Lp(a)-lowering effects were previously underestimated by commercial tests, while lepodisiran's effects were consistent across both methods.
View Article and Find Full Text PDF